Allergan to acquire Kythera Biopharmaceuticals

Leading global pharmaceutical company Allergan is to acquire Kythera Biopharmaceuticals in a cash and equity transaction valued at $2.1 billion.

The acquisition of Kythera immediately enhances Allergan’s global facial aesthetics portfolio with the addition of Kybella™ (deoxycholic acid) injection, the first and only approved non-surgical treatment for contouring moderate to severe submental fullness, commonly referred to as double chin. The acquisition will also add Kythera’s development product setipiprant (KYTH-105), a novel compound for the prevention of male pattern baldness, as well as additional early-stage development candidates.

“The acquisition of Kythera is a strategic investment that strengthens our leading global position in aesthetics and continues to position us for long-term growth,” said Brent Saunders, chief executive officer and president of Allergan.  “Kybella™ is an exciting new product that offers patients the first and only clinically-proven, non-surgical treatment for submental fullness (excess fat under the chin). As a leader in aesthetics, we know our customers are looking to offer their patients new options beyond traditional facial aesthetics.”

“Allergan’s world-class medical aesthetics, global footprint, history and commitment to developing leading aesthetic products makes them ideally suited to realize the maximum commercial potential of Kybella™,” said Keith Leonard, chief executive officer and president of Kythera.  “We look forward to working with Allergan to ensure a successful U.S. launch of Kybella™, as well as to secure additional approvals globally.”